Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep-Oct;91(5):601-603.
doi: 10.1590/abd1806-4841.20164935.

Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study

Affiliations

Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study

Anargyros Kouris et al. An Bras Dermatol. 2016 Sep-Oct.

Abstract

Background:: Bullous pemphigoid (BP) is a chronic, autoimmune blistering skin disease that affects patients' daily life and psychosocial well-being.

Objective:: The aim of the study was to evaluate the quality of life, anxiety, depression and loneliness in BP patients.

Methods:: Fifty-seven BP patients and fifty-seven healthy controls were recruited for the study. The quality of life of each patient was assessed using the Dermatology Life Quality Index (DLQI) scale. Moreover, they were evaluated for anxiety and depression according to the Hospital Anxiety Depression Scale (HADS-scale), while loneliness was measured through the Loneliness Scale-Version 3 (UCLA) scale.

Results:: The mean DLQI score was 9.45±3.34. Statistically significant differences on the HADS total scale and in HADS-depression subscale (p=0.015 and p=0.002, respectively) were documented. No statistically significant difference was found between the two groups on the HADS-anxiety subscale. Furthermore, significantly higher scores were recorded on the UCLA Scale compared with healthy volunteers (p=0.003).

Conclusion:: BP had a significant impact on quality of life and the psychological status of patients, probably due to the appearance of unattractive lesions on the skin, functional problems and disease chronicity.

PubMed Disclaimer

Conflict of interest statement

None

References

    1. Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172:867–877. - PubMed
    1. Teixeira VB, Cabral R, Brites MM, Vieira R, Figueiredo A. Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients. An Bras Dermatol. 2014;89:274–278. - PMC - PubMed
    1. Penha MÁ, Farat JG, Miot HA, Barraviera SR. Quality of life index in autoimmune bullous dermatosis patients. An Bras Dermatol. 2015;90:190–194. - PMC - PubMed
    1. Zhao CY, Murrell DF. Outcome measures for autoimmune blistering diseases. J Dermatol. 2015;42:31–36. - PubMed
    1. Sebaratnam DF, Hanna AM, Chee SN, Frew JW, Venugopal SS, Daniel BS, et al. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. JAMA Dermatol. 2013;149:1186–1191. - PubMed